Investigating plasma metabolites and their relationship to early breast cancer
Official title: The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
Run by Shengjing Hospital · NCT06698679 · Data updated 2026-11-12
This study is trying to see if certain substances in the blood can help identify breast cancer early and improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1000 (estimated) |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | November 15, 2024 |
| Main results expected | June 30, 2031 |
| Study ends | October 31, 2031 |
| Registry record updated | November 21, 2024 |
| Trial ID | NCT06698679 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include women with histologically confirmed breast cancer who have not received prior treatment, as well as healthy women without malignancies.
✕Probably not a fit
Patients with distant metastases or those with other malignant tumors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study explores the relationship between plasma metabolites and breast cancer to identify potential biomarkers for risk assessment and treatment efficacy. By analyzing plasma samples from both breast cancer patients and healthy controls, the study aims to uncover metabolic changes associated with the disease. The research incorporates clinical data, including cancer stage and treatment outcomes, to enhance understanding of how these metabolites correlate with prognosis. The ultimate goal is to establish a standardized metabolic profile that can aid in personalized therapy for breast cancer patients.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that improve early detection and treatment strategies for breast cancer.
How similar studies have gone: Other studies have shown promise in using metabolomics for cancer diagnosis and treatment, indicating a growing interest in this area, though this specific approach may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cohort 1 Control Group: women without breast cancer or other malignancies. Case Group: patients with histologically confirmed carcinoma in situ or invasive breast cancer; no prior treatment; no distant metastasis; and not associated with other malignant tumor diseases. * Cohort 2 Pathologically diagnosed as breast cancer; Treatment niave patients; To receive standard neoadjuvant therapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) . * Cohort 3 Patients who have been discharged after breast cancer treatment. Exclusion Criteria: * Histologically undiagnosed breast cancer. Breast cancer with distant metastases. Combined with other malignant tumors. Participants must not have participated in other clinical trials within the past month, unless those trials are observational or non-interventional in nature.
Where it's running
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China Recruiting
Study contacts
- Study coordinator: Liu Hua, Ph. D
- Email: 20242027@cmu.edu.cn
- Phone: 15140067366
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.